カタログ製品コード : C-EK21952/2

Mouse IL-1β Pro-form ELISA kit

*写真はイメージです
24T ¥47,000 (¥1,958/T) (税別)
48T ¥61,000 (¥1,271/T) (税別)
96T ¥69,800 (¥727/T) (税別)
標準納期 : 2週間
メーカー名 遺伝子名 種交差性 測定範囲 サンプル量 適用サンプル ドキュメント
MultiSciences IL-1β Pro-form Mouse 46.88 - 3000 pg/ml 20 μl 血清、血漿、細胞培養上清

保存方法 :

キットは未開封の場合、4℃で保管すること。 開封後は標準溶液を-20℃で保存し、他の試薬は4℃で保存すること。

構成内容 :

96-well polystyrene microplate coated with a monoclonal antibody against IL-1β Pro-form
Mouse IL-1β Pro-form Standard, lyophilized
IL-1β Pro-form Detect Antibody
Standard Diluent
Streptavidin-HRP
Assay Buffer (10×)
Substrate (TMB)
Stop Solution
Washing Buffer (20×)
Plate Covers

キーワード :

Mus musculus,Mouse,Interleukin-1 beta,IL-1 beta,Il1b

ターゲット情報 :

This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of mouse IL-1β Pro-form. The Mouse IL-1β Pro-form ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Interleukin-1 beta (IL-1β) is a proinflammatory cytokine expressed by monocytes, macrophages, and dendritic cells. It is synthesized in response to inflammatory stimuli as a 31 kDa inactive pro-form that accumulates in the cytosol. Cleavage of pro-IL-1β into the active 17 kDa protein requires the activation of inflammasomes. Inflammasome activation triggers the processing of the caspase-1 precursor into its active form, which in turn cleaves pro-IL-1β. Although IL-1β is most often secreted in its active form, secretion of the uncleaved protein may be detectable under some biological conditions.
IL-1β signals through two receptors, IL-1RI and IL-1RII. These cytokines play important roles in innate host defense by triggering the production of other proinflammatory cytokines in target cells and initiating acute-phase responses. Their activity can be moderated by IL-1 Receptor Antagonist (IL-1RA), a protein produced by many cell types that blocks receptor binding through competitive inhibition. Elevated levels of IL-1β have been associated with many chronic inflammatory conditions, giving IL-RA or IL-1β neutralizing antibodies potential therapeutical value.